ACD shortens the path to personalized medicine by unlocking the power of RNA biomarkers. Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. Based in the heart of Silicon Valley, ACD was founded and managed by experienced entrepreneurs in the life science industry. ACD’s products and services are based on its proprietary RNAscope® Technology, the first multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity. In addition to its ongoing efforts to develop proprietary diagnostic tests for cancer management, ACD also establishes partnerships with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development. These internal and external efforts will continue to position ACD as a leader in molecular diagnostics and companion diagnostics. The company’s technology overcomes critical hurdles in the identification and validation of biomarkers for companion diagnostics. ACD’s RNAscope® platform provides a new way of localizing and measuring RNA in situ with exceptional levels of sensitivity, specificity, and the ability to multiplex. Turnaround time for a new assay is reduced to three weeks. These advantages make the technology a powerful tool to address the issue of patient and disease heterogeneity, thus shortening the path to personalized medicine.
Independent of your genes of interest, thes easy RNA in situ hybridization assays use common reagents and protocols; providing universal assay conditions. All RNA-ISH kits contain reagents in a convenient ready-to-use (RTU) format, and chromogenic dyes are available to interrogate a single or two genes simultaneously. Most versatile are the RNAscope Multiplex Fluorescent Reagent Kits, enabling you to interrogate 1, 2 or 3 gen…
Independent of your genes of interest, our easy RNA in situ hybridization assay uses common reagents and protocols; providing universal assay conditions. All RNA-ISH kits contain reagents in a convenient ready-to-use (RTU) format, and chromogenic dyes are available to interrogate a single or two genes simultaneously.
The RNAscope Multiplex Fluorescent assays are ideal for simultaneous detection studies of any genes in nearly any tissue-type using fluorescent labels.
For labs that require high throughput and automated RNA in situ hybridization (ISH) analysis, ACD has partnered with Leica Biosystems and Roche Tissue Diagnostics to deliver RNAscope ISH automated assays.
The BaseScope™ Assay is a unique product from ACD, based on the same platform of proven and established RNAscope™ technology that has been cited in over 2300 publications. This powerful assay provides new data dimensions and unique insight into biological mechanisms. The BaseScope™ Assay enables applications such as the detection of exon junctions/splice variants, short/highly homologous RNA sequences (50-300 bases), and poin…
The RNAscope™ and BaseScope™ Assays are based on the proprietary RNAscope Technology enabling RNA target expression analysis within intact cells and tissues with high sensitivity and specificity. Using proprietary ACD RNAscope Probe Design Pipeline, we provide double "Z" oligo probes designed to hybridize to your specific RNA target of interest.
Introducing RNAscope HiPlex assay to expand your in situ hybridization potential.
The DNAscope chromogenic duplex (red/blue) staining allows researchers to use a standard bright-field microscope to visualize and quantify gene copy number variations (amplifications/deletions) and gene rearrangements/fusions in tissues with spatial and morphological context at single cell resolution.
The RNAscope Plus™ smRNA-RNA assay allows simultaneous detection of 1 smRNA and up to 3 RNA targets within a single sample using up to four target probes.
